CORE Study - Research Into Weight Management Services in the UK
NCT07559409 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 41000
Last updated 2026-05-07
Summary
Weight management services (previously known as Tier 3 services) represent a multidisciplinary specialist approach, available in community or secondary care settings. This tier caters to individuals with a Body Mass Index (BMI) greater than 35 (or over 30 if they have diabetes) and complex medical conditions, offering pharmacotherapy, low-energy liquid diets, and pre- and post-bariatric surgery care. Tier 4 services, located within secondary care, focus on bariatric surgery.
Data on obesity rates are systematically collected by the National Audit Office, enabling monitoring of Tier 1 effectiveness. Additionally, the National Bariatric Database provides insights into bariatric surgery rates, patient characteristics, and surgical outcomes.
However, comprehensive data on weight management services remain scarce, with information primarily available from only 4 of the 42 weight management clinics. Consequently, it is challenging to ascertain the availability of weight management services across different regions, the volume of referrals, the demographics of individuals accessing these services, and their outcomes during treatment. This lack of data hinders our ability to evaluate equitable access, appropriate referrals, and the overall effectiveness of these services throughout the UK.
Conditions
Sponsors & Collaborators
-
Society for Endocrinology
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-09-12
- Primary Completion
- 2027-12-31
- Completion
- 2027-12-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
Study of Patients Being Treated With Anti-obesity Medication
NCT06790160 ·Status: RECRUITING
-
A Feasibility Study to Determine the Most Appropriate Digital Dietary Assessment Tool in Patients With Obesity Initiating GLP-1 Receptor Agonist Treatment
NCT07194317 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
A Study of TG103 Injection in Non-diabetic Overweight or Obesity
NCT05997576 ·Status: COMPLETED ·Phase: PHASE3
-
Chinese, Overweight or Obesity, Real-World Registry Study
NCT07525037 ·Status: NOT_YET_RECRUITING
-
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist
NCT06500429 ·Status: COMPLETED ·Phase: PHASE2
-
Semaglutide 2.4 mg in Patients With Poor Weight-loss
NCT05073835 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease
NCT06501326 ·Status: RECRUITING ·Phase: PHASE4
-
Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults
NCT05786521 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
NCT07247084 ·Status: RECRUITING ·Phase: PHASE4
-
Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.
NCT07154238 ·Status: ENROLLING_BY_INVITATION
-
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
NCT05051579 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of Weekly Semaglutide Treatment on Energy Expenditure
NCT06390501 ·Status: COMPLETED ·Phase: NA
-
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
NCT06023095 ·Status: COMPLETED ·Phase: PHASE1
-
Young Adults With Early-onset Obesity Treated With Semaglutide
NCT05574439 ·Status: COMPLETED ·Phase: PHASE4
-
Understanding Acute Dietary Changes After GLP-1 Agonist Treatment: The GLaD Feasibility Study
NCT07001553 ·Status: COMPLETED
-
Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Multiple Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers
NCT01165502 ·Status: COMPLETED ·Phase: PHASE1
-
A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity
NCT07557953 ·Status: RECRUITING ·Phase: PHASE1
-
A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice
NCT07055607 ·Status: ENROLLING_BY_INVITATION
-
A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT07553299 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
NCT01557166 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Body Composition Changes With Weight Loss Interventions
NCT07115069 ·Status: RECRUITING
-
A Study of TG103 Injection in Overweight or Obesity
NCT05299697 ·Status: UNKNOWN ·Phase: PHASE2
-
A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet
NCT05429593 ·Status: COMPLETED ·Phase: PHASE1
-
A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).
NCT07081178 ·Status: TERMINATED
-
The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis
NCT02765399 ·Status: COMPLETED ·Phase: PHASE4